Detailed analysis of mucosal herpes simplex virus-2 replication kinetics with and without antiviral therapy

Journal of Antimicrobial Chemotherapy

Volumn 66, Issue 11, 2011, Pages 2593-2600

  Schiffer, Joshua T ^a,b   Magaret, Amalia ^a,b   Selke, Stacy ^a   Corey, Lawrence ^a,b   Wald, Anna ^a,b  

^a UNIVERSITY OF WASHINGTON   (United States)

^b Fred Hutchinson Cancer Research Center   (United States)

Author keywords

Aciclovir; Famciclovir; Viral dynamics

Indexed keywords

ACICLOVIR; FAMCICLOVIR; VALACICLOVIR;

ADULT; AGED; ANTIVIRAL THERAPY; ARTICLE; COMPARATIVE STUDY; CONTROLLED CLINICAL TRIAL (TOPIC); FEMALE; GENE DOSAGE; HERPES SIMPLEX VIRUS 2; HUMAN; MALE; NONHUMAN; POLYMERASE CHAIN REACTION; VIRUS REPLICATION; VIRUS SHEDDING;

2-AMINOPURINE; ACYCLOVIR; ADULT; AGED; ANTIVIRAL AGENTS; FEMALE; GENITALIA; HERPES GENITALIS; HERPESVIRUS 2, HUMAN; HUMANS; MALE; MIDDLE AGED; MUCOUS MEMBRANE; VALINE; VIRUS REPLICATION; VIRUS SHEDDING;

EID: 80054693148     PISSN: 03057453     EISSN: 14602091     Source Type: Journal    
DOI: 10.1093/jac/dkr346     Document Type: Article

References (35)

1. Elion GB, Furman PA, Fyfe JA et al. Selectivity of action of an antiherpetic agent, 9-(2-hydroxyethoxymethyl) guanine. Proc Natl Acad Sci USA 1977; 74: 5716-20.
2. Schaeffer HJ, Beauchamp L, de Miranda P et al. 9-(2-hydroxyethoxymethyl) guanine activity against viruses of the herpes group. Nature 1978; 272: 583-5.
3. Dorsky DI, Crumpacker CS. Drugs five years later: acyclovir. Ann Intern Med 1987; 107: 859-74.
4. Corey L, Benedetti J, Critchlow C et al. Treatment of primary first-episode genital herpes simplex virus infections with acyclovir: results of topical, intravenous and oral therapy. J Antimicrob Chemother 1983; 12 Suppl B: 79-88.
5. Douglas JM, Critchlow C, Benedetti J et al. A double-blind study of oral acyclovir for suppression of recurrences of genital herpes simplex virus infection. N Engl J Med 1984; 310: 1551-6.
6. Mindel A, Faherty A, Carney O et al. Dosage and safety of long-term suppressive acyclovir therapy for recurrent genital herpes. Lancet 1988; i: 926-8.
7. Raborn GW, McGaw WT, Grace M et al. Treatment of herpes labialis with acyclovir. Review of three clinical trials. Am J Med 1988; 85: 39-42.
8. Reichman RC, Badger GJ, Mertz GJ et al. Treatment of recurrent genital herpes simplex infections with oral acyclovir. A controlled trial. JAMA 1984; 251: 2103-7.
9. Rooney JF, Straus SE, Mannix ML et al. Oral acyclovir to suppress frequently recurrent herpes labialis. A double-blind, placebo-controlled trial. Ann Intern Med 1993; 118: 268-72.
10. Bartlett BL, Tyring SK, Fife K et al. Famciclovir treatment options for patients with frequent outbreaks of recurrent genital herpes: the RELIEF trial. J Clin Virol 2008; 43: 190-5.
11. Bodsworth N, Bloch M, McNulty A et al. 2-day versus 5-day famciclovir as treatment of recurrences of genital herpes: results of the FaST study. Sex Health 2008; 5: 219-25.
12. Wald A, Selke S, Warren T et al. Comparative efficacy of famciclovir and valacyclovir for suppression of recurrent genital herpes and viral shedding. Sex Transm Dis 2006; 33: 529-33.
13. Wald A, Corey L, Cone R et al. Frequent genital herpes simplex virus 2 shedding in immunocompetent women. Effect of acyclovir treatment. J Clin Invest 1997; 99: 1092-7.
14. Corey L, Wald A, Patel R et al. Once-daily valacyclovir to reduce the risk of transmission of genital herpes. N Engl J Med 2004; 350: 11-20.
15. Zhu J, Hladik F, Woodward A et al. Persistence of HIV-1 receptor-positive cells after HSV-2 reactivation is a potential mechanism for increased HIV-1 acquisition. Nat Med 2009; 15: 886-92.
16. Freeman E, Weiss H, Glynn J et al. Herpes simplex virus 2 infection increases HIV acquisition in men and women: systematic review and meta-analysis of longitudinal studies. AIDS 2006; 20: 73-83.
17. Wald A, Link K. Risk of human immunodeficiency virus infection in herpes simplex virus type 2-seropositive persons: a meta-analysis. J Infect Dis 2002; 185: 45-52.
18. Gray R, Wawer M, Brookmeyer R et al. Probability of HIV-1 transmission per coital act in monogamous, heterosexual, HIV-1-discordant couples in Rakai, Uganda. Lancet 2001; 357: 1149-53.
19. Celum C, Wald A, Hughes J et al. Effect of aciclovir on HIV-1 acquisition in herpes simplex virus 2 seropositive women and men who have sex with men: a randomised, double-blind, placebo-controlled trial. Lancet 2008; 371: 2109-19.
20. Watson-Jones D, Weiss HA, Rusizoka M et al. Effect of herpes simplex suppression on incidence of HIV among women in Tanzania. N Engl J Med 2008; 358: 1560-71.
21. Celum C, Wald A, Lingappa JR et al. Acyclovir and transmission of HIV-1 from persons infected with HIV-1 and HSV-2. N Engl J Med 2010; 362: 427-39.
22. Hadinoto V, Shapiro M, Sun CC et al. The dynamics of EBV shedding implicate a central role for epithelial cells in amplifying viral output. PLoS Pathog 2009; 5: e1000496.
23. Schiffer J, Wald A, Selke S et al. The kinetics of mucosal herpes simplex virus-2 infection in humans: evidence for rapid viral-host interactions. J Infect Dis 2011; 204: 554-61.
24. Gupta R, Wald A, Krantz E et al. Valacyclovir and acyclovir for suppression of shedding of herpes simplex virus in the genital tract. J Infect Dis 2004; 190: 1374-81.
25. Magaret A, Wald A, Huang M et al. Optimizing PCR positivity criterion for detection of herpes simplex virus DNA on skin and mucosa. J Clin Microbiol 2007; 45: 1618-20.
26. Odell PM, Anderson KM, D'Agostino RB. Maximum likelihood estimation for interval-censored data using a Weibull-based accelerated failure time model. Biometrics 1992; 48: 951-9.
27. Ashley RL, Militoni J, Lee F et al. Comparison of western blot (immunoblot) and glycoprotein G-specific immunodot enzyme assay for detecting antibodies to herpes simplex virus types 1 and 2 in human sera. J Clin Microbiol 1988; 26: 662-7.
28. Jerome KR, Huang ML, Wald A et al. Quantitative stability of DNA after extended storage of clinical specimens as determined by real-time PCR. J Clin Microbiol 2002; 40: 2609-11.
29. Corey L, Huang ML, Selke S et al. Differentiation of herpes simplex virus types 1 and 2 in clinical samples by a real-time taqman PCR assay. J Med Virol 2005; 76: 350-5.
30. Zhu J, Koelle D, Cao J et al. Virus-specific CD8+ T cells accumulate near sensory nerve endings in genital skin during subclinical HSV-2 reactivation. J Exp Med 2007; 204: 595-603.
31. Schiffer JT, Abu-Raddad L, Mark KE et al. Mucosal host immune response predicts the severity and duration of herpes simplex virus-2 genital tract shedding episodes. Proc Natl Acad Sci USA 2010; 107: 18973-8.
32. Gupta R, Hill E, McClernon D et al. Acyclovir sensitivity of sequential herpes simplex virus type 2 isolates from the genital mucosa of immunocompetent women. J Infect Dis 2005; 192: 1102-7.
33. Corey L, Adams HG, Brown ZA et al. Genital herpes simplex virus infections: clinical manifestations, course, and complications. Ann Intern Med 1983; 98: 958-72.
34. Mark KE, Wald A, Magaret AS et al. Rapidly cleared episodes of herpes simplex virus reactivation in immunocompetent adults. J Infect Dis 2008; 198: 1141-9.
35. Schiffer JT, Abu-Raddad L, Mark KE et al. Frequent release of low amounts of herpes simplex virus from neurons: results of a mathematical model. Sci Transl Med 2009; 1: 7ra16.